News – Page 389 – Endpoints News

Rise in consumer convenience disrupts traditional pharma-to-physician marketing, ZS research finds

3 years ago

Manufacturing roundup: Life sciences development planned for Texas; Eli Lilly to supply insulin ingredient to ...

3 years ago

Applied Therapeutics showcases early data in PhIII rare sugar disease trial

3 years ago

Pfizer gives interim update on PARP inhibitor combo treatment, earns priority review at FDA

3 years ago

Flagship company teams up with Charles River for AI drug discovery

3 years ago

CAR-T biotech reduces staff as it hunts for capital to enter clinic next year

3 years ago

Talaris discontinues two trials, cuts staff and starts ‘strategic alternatives’ search

3 years ago

Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs

3 years ago

Exclusive: Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission

3 years ago

Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer

3 years ago

'Rare outliers': Feng Zhang eyes a new path to genetic medicine delivery with ex-Alnylam leaders and $193M

3 years ago

Drug prices 'not justified' by pharma R&D spending, new study says

3 years ago

Over-the-counter Narcan gets unanimous thumbs-up from FDA advisors

3 years ago

The top 100 biotech VCs: Who's staying at the table and what do they want now?

3 years ago

Spain's Grifols to dismiss more than 2,000 US employees in $427M cost savings bid

3 years ago

Asahi Kasei finishes $96M+ pharma excipient manufacturing plant in Japan

3 years ago

Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue

3 years ago

Moderna promises to provide vaccines at no out-of-pocket cost

3 years ago

Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up

3 years ago

AlloVir unwraps PhII data of cell therapy in expanded transplant indication, leaves trial plans up in the air

3 years ago

ImmunityBio, Codagenix and EuMentis raise funds, while a biotech SPAC dissolves

3 years ago

FDA to review Galera’s drug for radiotherapy complication, biotech immediately seeks $30M

3 years ago

Updated: J&J returns rights to early-stage, RNAi NASH candidate to Arrowhead

3 years ago

Cullinan Oncology drops $25M upfront for candidate from Harbour

3 years ago

First page Previous page 386 387 388389390 391 392 Next page Last page